Elotuzumab

Elotuzumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Relapsed Refractory Multiple Myeloma (RRMM)、Myeloma、Multiple Myeloma、Refractory Multiple Myeloma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Elotuzumab 研究

• Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

  III 期招募中美国NCT07772024

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  III 期招募中美国Argentina澳大利亚比利时NCT06152575

• Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  III 期招募中美国澳大利亚Brazil加拿大NCT07555938

• Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

  I 期 / II 期招募中美国NCT06518551

• Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

  I 期 / II 期招募中美国NCT06785415

• Selinexor and Backbone Treatments of Multiple Myeloma Patients

  I 期 / II 期招募中美国加拿大NCT02343042

• A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  III 期招募中美国澳大利亚比利时BrazilNCT05730036

• GMMG Multiple Myeloma Registry

  不适用招募中德国NCT07111884

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。